✨
AI Summary
- Boehringer Ingelheim's US launch strategy covers ILD, cardiometabolic, and obesity markets.
- Private ownership enables long-term decision-making and strategic investments.
- Brian Hilberdink aims to reframe the obesity conversation beyond weight loss.
Guests on This Episode
BH
Brian Hilberdink
1 podcast appearance